Healthcare -
Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 9.28
-0.215 %
$ 598 M
Market Cap
-10.43
P/E
1. INTRINSIC VALUE
Balance Sheet
Evolus, Inc.
| Current Assets | 151 M |
| Cash & Short-Term Investments | 87 M |
| Receivables | 47.7 M |
| Other Current Assets | 16.7 M |
| Non-Current Assets | 81.2 M |
| Long-Term Investments | 0 |
| PP&E | 10.4 M |
| Other Non-Current Assets | 70.8 M |
| Current Liabilities | 63 M |
| Accounts Payable | 9.24 M |
| Short-Term Debt | 1.72 M |
| Other Current Liabilities | 52 M |
| Non-Current Liabilities | 164 M |
| Long-Term Debt | 128 M |
| Other Non-Current Liabilities | 35.8 M |
EFFICIENCY
Earnings Waterfall
Evolus, Inc.
| Revenue | 266 M |
| Cost Of Revenue | 84 M |
| Gross Profit | 182 M |
| Operating Expenses | 217 M |
| Operating Income | -34.4 M |
| Other Expenses | 16 M |
| Net Income | -50.4 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Evolus, Inc.
| Net Income | -50.4 M |
| Depreciation & Amortization | 6.02 M |
| Capital Expenditures | -1.47 M |
| Stock-Based Compensation | 22.3 M |
| Change in Working Capital | -6.6 M |
| Others | 10.8 M |
| Free Cash Flow | -19.5 M |
Wall Street Analysts Price Targets
Evolus, Inc.
Wall Street analysts predict an average 1-year price target for EOLS of $24 , with forecasts ranging from
a
low of
$20 to a high of $27 .
EOLS Lowest Price Target
Wall Street Target
20 USD
115.52%
EOLS Average Price Target
Wall Street Target
24 USD
158.62%
EOLS Highest Price Target
Wall Street Target
27 USD
190.95%
4. DIVIDEND
ANALYSIS
EOLS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Evolus, Inc.
Sold
0-3 MONTHS
1.61 M USD 3
3-6 MONTHS
2.24 M USD 5
6-9 MONTHS
0 USD 0
9-12 MONTHS
138 K USD 2
Bought
189 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in June of non-qualified stock options to purchase an aggregate of 11,628 shares of Evolus and an aggregate of 36,077 restricted stock units (RSUs) of the company's common stock to 17 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's.
businesswire.com
- 1 week ago
Evolysse™ Recognized in 2025 Shape Skin Awards
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, is proud to announce it has been recognized with two Shape 2025 Skin Awards: Evolysse™ Recognized as the Best Filler for 2025 with its recently launched injectable hyaluronic acid gel line Best Membership Treatment Model for Club Evolus™, its proprietary consumer rewards program The annual Shape Skin Awards highlight innovation and.
businesswire.com
- 1 week ago
Evolus Announces Departure of its Chief Financial Officer
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that its Chief Financial Officer, Sandra Beaver, has resigned effective June 13, 2025, to accept the same position at a private mental health and wellness technology company. Ms. Beaver's resignation is not a result of any disagreement related to the company's operations, policies or practices, including any account.
businesswire.com
- 3 weeks ago
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the publication of the U.S. pivotal study results for Evolysse™ Form and Evolysse™ Smooth in the Aesthetic Surgery Journal, a leading peer-reviewed journal focusing on advances in aesthetic medicine and surgery. The multicenter, randomized, controlled, double-blind study followed 140 patients through 12 months and e.
businesswire.com
- 1 month ago
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in May of non-qualified stock options to purchase an aggregate of 12,706 shares of Evolus and an aggregate of 40,576 restricted stock units (RSUs) of the company's common stock to 16 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's b.
businesswire.com
- 1 month ago
Evolus, Inc. (EOLS) Reports Q1 Loss, Misses Revenue Estimates
Evolus, Inc. (EOLS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.13 per share a year ago.
zacks.com
- 1 month ago
Evolus, Inc. (EOLS) Q1 2025 Earnings Call Transcript
Evolus, Inc. (NASDAQ:EOLS ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Nareg Sagherian - VP, Head of Global IR and Corporate Communications David Moatazedi - President and CEO Sandra Beaver - CFO Conference Call Participants Annabel Samimy - Stifel Marc Goodman - Leerink Partners Navann Ty - BNP Paribas Serge Belanger - Needham Doug Tsao - H.C. Wainwright Sam Eiber - BTIG Operator Good afternoon, everyone.
seekingalpha.com
- 1 month ago
Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has entered into an amended and restated credit facility, replacing its existing $125 million credit agreement with a new $250 million credit facility with funds managed by Pharmakon Advisors, LP. Highlights of the new facility include: Lowered Interest Rate: Reduced borrowing cost by 350 basis points (bps) based.
businesswire.com
- 1 month ago
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know
Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
- 1 month ago
Evolus to Report First Quarter Financial Results on May 7, 2025
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2025 financial results on Wednesday, May 7, 2025, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To par.
businesswire.com
- 1 month ago
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in April of an aggregate of 30,579 restricted stock units (RSUs) of the company's common stock to 13 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with a grant d.
businesswire.com
- 2 months ago
Evolus Announces Commercial Launch of Evolysse™
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the commercial launch date for Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse™ collection, scheduled for Friday, April 18th. To support the introduction, Evolus will initiate a comprehensive educational rollout beginning with a national Evolus Academy webcast for health.
businesswire.com
- 2 months ago
8. Profile
Summary
Evolus, Inc. EOLS
COUNTRY
US
INDUSTRY
Drug Manufacturers - Specialty & Generic
MARKET CAP
$ 598 M
Dividend Yield
0.00%
Description
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Contact
520 Newport Center Drive, Newport Beach, CA, 92660
https://www.evolus.com
IPO
Date
Feb. 8, 2018
Employees
372
Officers
Ms. Tomoko Yamagishi-Dressler
Chief Marketing Officer
Ms. Jessica Novak
Senior Vice President of Human Resources
Mr. Jeffrey J. Plumer
General Counsel
Mr. David Moatazedi
President, Chief Executive Officer & Director
Dr. Rui Avelar C.CFP, Dip.SportMed, M.D.
Chief Medical Officer and Head of Research & Development
Mr. Nareg Sagherian
Head of Global Investor Relations & Corporate Communications
Mr. Kurt Knab
Senior Vice President of Sales
Ms. Sandra Beaver
Chief Financial Officer